Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
Open Access
- 1 July 2010
- journal article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 87
Abstract
Thymoquinone (TQ) is a compound extracted from Black Caraway seeds of Nigella Sativa and is active against various cancers. Cisplatin (CDDP) is the most active chemotherapeutic agent in Lung Cancer. Here we report activity of TQ against non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines alone and in combination with Cisplatin (CDDP).Keywords
This publication has 28 references indexed in Scilit:
- Structure-Activity Studies on Therapeutic Potential of Thymoquinone Analogs in Pancreatic CancerPharmaceutical Research, 2010
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathwaysMolecular Cancer Therapeutics, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- The Functional Role of the ELR Motif in CXC Chemokine-mediated AngiogenesisJournal of Biological Chemistry, 1995
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences of the United States of America, 1979
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970